Adjuvant Therapy in Melanoma: COMBI-AD Trial

Source: OnClive, December 2018

Transcript:

Axel Hauschild, MD: So my question for Caroline is on adjuvant treatment modalities. There was an update on COMBI-AD at this year’s ESMO [European Society for Medical Oncology] conference, and the data were published on the same day. Can you summarize the findings of this clinical trial and also remind us on the design of the clinical trial?

Caroline Robert, MD, PhD: Yes, it was a randomized phase III trial with 2 arms – placebo versus dabrafenib plus trametinib.

We already have seen the results. They have been published in the New England Journal of Medicine. We know that we have a very significant benefit in terms of relapse-free survival with a ratio of 0.47. We also have the 3-year overall survival data that statistically did not really reach the prespecified points, but we all know there are very good results.